- Fresenius Kabi’s first U.S. biosimilar launch
- Provides accessible, high-quality treatment option for U.S. cancer patients undergoing chemotherapy to reduce the incidence of infection as manifested by febrile neutropenia
- Strengthens Fresenius Kabi’s heritage in oncology and its commitment to oncology patients
- The expansion of the company’s global biosimilars portfolio focused on oncology and immunology is a significant key milestone in the company’s Vision 2026 growth strategy
Fresenius Kabi, a global health care company that specializes in pharmaceuticals, medical technologies, and nutrition products for critical and chronic conditions, announced today the launch of its pegfilgrastim biosimilar, Stimufend® (pegfilgrastim-fpgk), in the United States (U.S.).
Stimufend® was approved by the United States (U.S.) Food and Drug Administration (FDA) in September 2022 for use in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Read complete press release HERE.